SynthesisPloS one2014
A systematic review of cost-sharing strategies used within publicly-funded drug plans in member countries of the organisation for economic co-operation and development.
Synthesis in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Portable Normothermic Cardiac Perfusion System in Donation After Cardiocirculatory Death: A Health Technology Assessment.Ontario health technology assessment series · 2020Pooled it
- Shifting care from hospitals to general practice from the health insurers' perspective: an interview study.BMC health services research · 2025Article
- Health Canada advisory impacts on the prevalence of oral codeine use in the Pediatric Canadian population: comparative study across provinces.Scientific reports · 2024Article
- Community pharmacists' views about prescription medicine co-payments and potential implications for equitable access to medicines: a critical realist interpretation.Journal of pharmaceutical policy and practice · 2023Article
- Exploring the effectiveness of demand-side retail pharmaceutical expenditure reforms : Cross-country evidence from weighted-average least squares estimation.International journal of health economics and management · 2023Article
- In search of a 'pan-European value set'; application for EQ-5D-3L.BMC medical research methodology · 2023Article
- Factors Associated with Willingness to Pay for Cost-Sharing under Universal Health Coverage Scheme in Yogyakarta, Indonesia: A Cross-Sectional Survey.International journal of environmental research and public health · 2022Article
- Public policy coverage and access to medicines in Brazil.Revista de saude publica · 2022Observational
- The Effect of Changes in Cost Sharing on the Consumption of Prescription and Over-the-Counter Medicines in Catalonia.International journal of environmental research and public health · 2021Article
- Co-payment for Unfunded Additional Care in Publicly Funded Healthcare Systems: Ethical Issues.Journal of bioethical inquiry · 2019Review
- The Economic Burden of Breast Cancer Survivors in Korea: A Descriptive Study Using a 26-Month Micro-Costing Cohort Approach.Asian Pacific journal of cancer prevention : APJCP · 2019Article
- Private provision of social insurance: drug-specific price elasticities and cost sharing in Medicare Part D.American economic journal. Economic policy · 2018Article
- Regulating pharmaceutical companies' financial largesse.Israel journal of health policy research · 2018Article
- Drug coverage in Canada: gaps and opportunities.Journal of psychiatry & neuroscience : JPN · 2018Article
- Comparison of Canadian public medication insurance plans and the impact on out-of-pocket costs.CMAJ open · 2017Article
- Article
- Universal prescription drug coverage in Canada: Long-promised yet undelivered.Healthcare management forum · 2016Review
- Assessing outcomes of enhanced chronic disease care through patient education and a value-based formulary study (ACCESS)-study protocol for a 2×2 factorial randomized trial.Implementation science : IS · 2016Article
- Catastrophic Health Care Expenditure among Older People with Chronic Diseases in 15 European Countries.PloS one · 2016Article
- Commentary: Patient Cost Sharing and Medical Expenditures for the Elderly.Frontiers in pharmacology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPublicly-funded drug plans vary in strategies used and policies employed to reduce continually increasing pharmaceutical expenditures. We systematically reviewed the utilization of cost-sharing strategies and physician-directed prescribing regulations in publicly-funded formularies within member nations of the Organization of Economic Cooperation and Development (OECD). METHODS &
findingsUsing the OECD nations as the sampling frame, a search for cost-sharing strategies and physician-directed prescribing regulations was done using published and grey literature. Collected data was verified by a system expert within the prescription drug insurance plan in each country, to ensure the accuracy of key data elements across plans. Significant variation in the use of cost-sharing mechanisms was seen. Copayments were the most commonly used cost-containment measure, though their use and amount varied for those with certain conditions, most often chronic diseases (in 17 countries), and by socio-economic status (either income or employment status), or with age (in 15 countries). Caps and deductibles were only used by five systems. Drug cost-containment strategies targeting physicians were also identified in 24 countries, including guideline-based prescribing, prescription monitoring and incentive structures.
conclusionsThere was variable use of cost-containment strategies to limit pharmaceutical expenditures in publicly funded formularies within OECD countries. Further research is needed to determine the best approach to constrain costs while maintaining access to pharmaceutical drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.